The Deloitte Intelligent biopharma series explores how artificial intelligence (AI) technologies will affect each step of the biopharma value chain.
This report, the second in our series, examines how AI is helping to accelerate the efficiency and cost-effectiveness of drug discovery.
The pace and scale of medical and scientific innovation is transforming the biopharma industry. The need for better patient engagement and experience is spurring new business models. Data generated, captured,…
A major new report led by the Novartis Foundation and Microsoft shows how investment in data and AI is critical to drive the health system improvements needed to respond to…
After several months of crisis, Medicines for Europe lays out some of the key lessons learned from COVID-19 for the future of pharmaceutical policy in Europe. The COVID-19 outbreak in…
See our Cookie Privacy Policy Here
